DeepMed Research

Fesoterodine

Generic Name: Fesoterodine

Brand Names: Toviaz

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₇NO_₃

CAS Number: 286930-02-7

Unique Ingredient Identifier: 621G617227

Background: Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Indication: 适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。

Associated Conditions: Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)

Clinical Trials

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Phase 1

Completed

Conditions: Neurogenic Detrusor Overactivity

Interventions: Drug: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Drug: Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)
Drug: Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)
Drug: Fesoterodine BIC SR4 fed (Treatment E in Part B)
Drug: Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)

First Posted Date: 2020-07-01

Last Posted Date: 2021-02-10

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT04452838

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

Fall Prevention in Older Adults With OAB

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: Fesoterodine

First Posted Date: 2019-05-10

Last Posted Date: 2023-05-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 74

Registration Number: NCT03946124

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Drug: mirabegron
Drug: solifenacin
Drug: darifenacin
Drug: imidafenacin
Drug: tolterodine
Drug: oxybutynin
Drug: trospium
Drug: fesoterodine
Drug: propiverine

First Posted Date: 2018-07-27

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Singapore Pte. Ltd.

Target Recruit Count: 5589

Registration Number: NCT03602508

Locations: 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷
Site KR82001, Seoul, Korea, Republic of

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Device: solifenacin
Drug: mirabegron
Drug: darifenacin
Drug: imidafenacin
Drug: tolterodine
Drug: oxybutynin
Drug: trospium
Drug: fesoterodine
Device: propiverine

First Posted Date: 2018-06-28

Last Posted Date: 2020-04-22

Lead Sponsor: Astellas Pharma Singapore Pte. Ltd.

Target Recruit Count: 805

Registration Number: NCT03572231

Locations: 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷
Site KR410009, Incheon, Korea, Republic of
🇰🇷
Site KR410005, Kangam, Korea, Republic of

and more 12 locations

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

Phase 2

Completed

Conditions: Autonomic Dysreflexia

Interventions: Drug: Fesoterodine

First Posted Date: 2016-02-08

Last Posted Date: 2019-09-09

Lead Sponsor: University of British Columbia

Target Recruit Count: 15

Registration Number: NCT02676154

Locations: 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Fesoterodine

First Posted Date: 2015-11-25

Last Posted Date: 2019-07-30

Lead Sponsor: Stéphane Bolduc

Target Recruit Count: 26

Registration Number: NCT02614482

Locations: 🇨🇦
CHU de Québec-Université Laval, Québec City, Quebec, Canada

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Phase 3

Completed

Conditions: Urinary Bladder, Neurogenic

Interventions: Drug: Fesoterodine BIC 2 mg
Drug: Fesoterodine PR 4 mg
Drug: Fesoterodine BIC 4 mg
Drug: Fesoterodine PR 8 mg

First Posted Date: 2015-07-17

Last Posted Date: 2020-11-30

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT02501928

Locations: 🇯🇵
Fukuoka Children's Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵
Osaka Women's and Children's Hospital, Izumi-shi, Osaka, Japan

and more 4 locations

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Phase 4

Terminated

Conditions: Parkinson Disease
Urinary Bladder, Overactive

Interventions: Drug: Fesoterodine
Drug: Placebo

First Posted Date: 2015-03-11

Last Posted Date: 2019-09-26

Lead Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Target Recruit Count: 5

Registration Number: NCT02385500

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Oxybutynin XL
Drug: Fesoterodine

First Posted Date: 2014-12-31

Last Posted Date: 2019-07-30

Lead Sponsor: Stéphane Bolduc

Target Recruit Count: 62

Registration Number: NCT02327936

Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older

Phase 2

Terminated

Conditions: Nocturia

Interventions: Drug: Desmopressin
Drug: Fesoterodine

First Posted Date: 2014-10-13

Last Posted Date: 2016-11-15

Lead Sponsor: Mount Sinai Hospital, Canada

Target Recruit Count: 4

Registration Number: NCT02262936

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy